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Abstract
Objectives—We aimed to explore the effects of pharmacologic inhibition of cannabinoid-1
(CB1) receptor in in vivo and in vitro models of doxorubicin (DOX)-induced cardiotoxicity.
Background—Doxorubicin is one of the most potent antitumor agents available; however, its
clinical use is limited because of the risk of severe cardiotoxicity. Endocannabinoids mediate
cardiodepressive effects through CB1 receptors in various pathophysiological conditions, and these
effects can be reversed by CB1 antagonists.
Methods—Left ventricular function was measured by Millar pressure-volume system. Apoptosis
markers, CB1/CB2 receptor expression, and endocannabinoid levels were determined by
immunohistochemistry, Western blot, reverse transcription-polymerase chain reaction, real-time
polymerase chain reaction, flow cytometry, fluorescent microscopy, and liquid chromatography/in-
line mass spectrometry techniques.
Results—Five days after the administration of a single dose of DOX (20 mg/kg intraperitoneally)
to mice, left ventricular systolic pressure, maximum first derivative of ventricular pressure with
respect to time (+dP/dt), stroke work, ejection fraction, cardiac output, and load-independent indexes
of contractility (end-systolic pressure–volume relation, preload-recruitable stroke work, dP/dt–end-
diastolic volume relation) were significantly depressed, and the myocardial level of the
endocannabinoid anandamide (but not CB1/CB2 receptor expression) was elevated compared with
vehicle-treated control mice. Treatment with the CB1 antagonists rimonabant or AM281 markedly
improved cardiac dysfunction and reduced DOX-induced apoptosis in the myocardium. Doxorubicin
also decreased cell viability and induced apoptosis in the H9c2 myocardial cell line measured by
flow cytometry and fluorescent microscopy, which were prevented by the preincubation of the cells
with either CB1 antagonist, but not with CB1 and CB2 agonists and CB2 antagonists.
Conclusions—These data suggest that CB1 antagonists may represent a new cardioprotective
strategy against DOX-induced cardiotoxicity.
Doxorubicin (DOX) (adriamycin) is one of the most potent broad-spectrum antitumor
anthracycline antibiotics commonly used to treat a variety of cancers, including severe
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leukemias, lymphomas, and solid tumors (1–3). However, the clinical use of DOX is limited
because of its serious cardiotoxicity, which often leads to irreversible degenerative
cardiomyopathy and heart failure (3).
The mechanism of DOX-induced cardiotoxicity involves increased oxidative/nitrosative stress
(4–7), matrix metalloproteinase activation (8,9), and alteration of cardiac energetics (10),
which eventually lead to cell death by apoptosis or cell necrosis (11–15). However, the exact
mechanisms have not been fully established, and optimal therapeutic approaches for
cardioprotection remain undefined (3).
Endocannabinoids and their synthetic analogs exert powerful cardiodepressive effects
mediated through cannabinoid-1 (CB1) receptors (16,17), which have recently been implicated
in the mechanism of hypotension associated with hemorrhagic, endotoxic, and cardiogenic
shock, and advanced liver cirrhosis, and these effects can be prevented or reversed by treatment
with CB1 antagonists (16,17). Furthermore, the CB1 antagonist rimonabant is emerging as a
novel therapeutic agent for obesity and related cardiometabolic risk factors in humans (17–
20). Here, we explore the effects of 2 CB1 antagonists, rimonabant and AM281, on DOX-
induced cardiac dysfunction and cardiotoxicity both in vivo and in vitro.
Materials and Methods
Animals
All protocols were approved by the Institutional Animal Care and Use Committee and were
performed in accordance with the National Institutes of Health (NIH) Guide for the Care and
Use of Laboratory Animals. Male C57BL/6J mice weighing 25 to 35 g were administered a
single dose of DOX HCl (Sigma/Aldrich, St. Louis, Missouri) at 20 mg/kg intraperitoneally,
and used for functional measurements 5 days later when severe cardiac dysfunction is well
established (6,14,15,21,22). Treatment with the CB1 antagonists AM281 or rimonabant
(SR141716; 10 mg/kg intraperitoneally, respectively) started 1.5 h before the DOX injection
and continued (10 mg/kg intraperitoneally/day) until the hemodynamic measurements were
made.
Hemodynamic measurements in mice
Left ventricular performance was analyzed in mice anesthetized with 2% isoflurane by using
1-F microtip pressure-volume catheter (PVR 1045) and ARIA pressure–volume conductance
system (Millar Instruments, Houston, Texas) coupled to a Powerlab/4SP A/D converter (AD
Instruments, Mountain View, California) as described (6) (also see the Appendix).
Reagents, antibodies, and cell culture
Doxorubicin was purchased from Sigma Chemical. AM281, AM630, JWH133, and HU210
were purchased from Tocris (Baldwin, Missouri). SR144528 and rimonabant (SR141716) are
from the National Institute on Drug Abuse Drug Supply Program (Research Triangle Park,
North Carolina). Antibodies used are anti-actin mAb (Chemicon, Temecula, California), anti-
caspase 3 mAb (Cell Signaling, Danvers, Massachusetts), and anti-active caspase-3 (Cell
Signaling).
Rat embryonic ventricular myocardial H9c2 cells were obtained from American Type Culture
Collection (Manassas, Virginia). Cells were cultured in DMEM (GIBCO, Invitrogen, Carlsbad,
California) containing 10% fetal bovine serum (Invitrogen), 100 U/ml penicillin, and 100 μg/
ml streptomycin at 37°C in a humidified atmosphere of 5% CO2 as described (23). Cells were
always used at <80% of confluence.
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Real-time polymerase chain reaction and reverse transcription-polymerase chain reaction
analyses were performed from hearts and H9c2 cells for caspase-3, caspase-9, and CB1/2
receptor gene expression as detailed in the Appendix.
Western immunoblot analyses
Protein was extracted from tissue homogenates using radioimmunoprecipitation assay lysis
buffer, containing protease inhibitor cocktail set III and phosphatase inhibitor cocktail set I
(Calbiochem, EMD Biosciences, San Diego, California). Protein was measured by Dc protein
assay kit (Bio-Rad, Hercules, California), and equal amounts (40 μg per lane) were fractionated
on NuPAGE 4% to 12% Bis-Tris gel (Invitrogen) and transferred onto nitrocellulose membrane
(Invitrogen) using a semidry transfer apparatus (Bio-Rad). The blots were detected with
Supersignal West Pico chemiluminescent substrate (Pierce Biotechnology, Rockford, Illinois)
and developed using Kodak Biomax film (PerkinElmer, Wellesley, Massachusetts).
Immunoblots were scanned with Epson V750 Pro scanner and quantification after background
correction was carried out by ImageQuant5.1 software (GE Healthcare, Piscataway, New
Jersey); all values were normalized to beta-actin.
Cell viability assay
Cells were seeded at a density of 1 × 105 cells in 96 well plates, and cell viability was assessed
via conventional XTT assays (Roche, Indianapolis, Indiana). After incubation, the cells were
treated for 6 h with XTT solution at 37°C. The absorbance was measured at 570 nm using an
enzyme-linked immunosorbent assay reader (SpectramaxPro, Molecular Devices, Union City,
California).
Flow cytometry
Early apoptosis and cytotoxity is determined by flow cytometry using propidium iodide and
Annexin V staining (Molecular Probes, Invitrogen, Carlsbad, California) according to
manufacturer’s recommendation. The cells were trypsinized for a very short time and collected
via centrifugation at 1,000 μg for 5 min. The harvested cells were then washed with phosphate-
buffered saline. The cells were resuspended at a density of 1 × 106 cells/ml in Hank’s balanced
salt solution buffer containing calcium and magnesium. Flow-cytometry analyses included
10,000 events using a FACSCalibur (Becton Dickinson, San Jose, California). The data were
acquired and analyzed using Cell Quest program (Becton Dickinson).
Fluorescence microscopy, DNA fragmentation assay, myocardial terminal
deoxynucleotidyltransferase-mediated nick-end labeling (TUNEL) staining, and assay and
caspase 3 activity were used according to manufacturer’s instructions as described in the
Appendix.
Measurement of endocannabinoid levels
The levels of anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were quantified by liquid
chromatography/in-line mass spectrometry as detailed in the Appendix.
Statistical analysis
Results are reported as mean ± standard error of the mean. Probability values of p < 0.05 were
considered significant. For detailed statistical analysis see the Appendix.
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Results
CB1 antagonists improve DOX-induced cardiac dys-Function
Treatment of mice with DOX, 20 mg/kg intra-peritoneally, induced a significant decrease in
heart rate, left ventricular systolic pressure, maximum first derivative of ventricular pressure
with respect to time (+dP/dt), −dP/dt, stroke work, ejection fraction, cardiac output, and load-
independent indexes of contractility (preload-recruitable stroke work, dP/dt–end-diastolic
volume relation, and end-systolic pressure–volume relation, respectively), and an increase in
left ventricular end-diastolic pressure and prolongation of relaxation time constants (τ Weiss
and Glantz) (Figs. 1 and 2). Treatment with rimonabant or AM281 (10 mg/kg−1
intraperitoneally) immediately before and daily for 5 days after DOX treatment significantly
attenuated the DOX-induced changes in ventricular function (Figs. 1 and 2). In vehicle-treated
control animals, rimonabant or AM281 exerted no significant effects on the hemodynamic
parameters studied (Fig. 1).
CB1 antagonists protect against DOX-induced cell death in rat embryonic ventricular
myocardial-derived H9c2 cells in vitro
Incubation of cells with 1 or 5 μmol/l DOX for 18 h resulted in significant decreases in cell
viability, measured by a colorimetric XTT-based cell viability assay to 78.6 ± 1.6% or 74.4 ±
1.2%, respectively. Doxorubicin-induced cell death at 1 and 5 μmol/l was completely prevented
by 2 h of preincubation (followed by continuous treatment during the 18 h DOX exposure)
with 1 μmol/l AM281 (98.0 ± 4.5% and 95.3 ± 5.1%) or rimonabant (96.5 ±3.6% and 102.0 ±
4.3%, respectively) (Fig. 3A). Cannabinoid-1 receptor antagonists alone did not have any effect
on cell viability (data not shown).
CB1 antagonists, but not CB1 and CB2 agonists and CB2 antagonists, prevent DOX-induced
apoptosis in vitro
The H9c2 cell line was subjected to flow cytometric analysis for apoptotic and total dead cells
by Annexin V and propidium iodide staining. Early apoptotic marker Annexin V was
significantly increased in cells exposed to 1 μmol/l DOX for 18 h but remained at control levels
in cells pretreated with either 1 μmol/l AM281 or rimonabant starting from 2 h before DOX
administration (Fig. 3B). The DOX-induced total cell death as indicated by positive propidium
iodide staining (Fig. 3B) confirmed recent cell viability data, including the higher level of
propidium iodide staining in apoptotic compared with normal cells (14). Activation of caspase
is a key downstream event of apoptosis. We measured the active form of caspase by
fluorescence microscopy. As an indication of caspase activity, green color is generated by
cleavage of a generic caspase substrate (rhodamine 110, bis-[L-aspartic acid amide],
trifluoroacetic acid salt) introduced into live cells. The green color was conspicuously present
in all DOX-treated H9c2 cells (Fig. 3C). In contrast, the green fluorescence was completely
absent in cells treated with 1 μmol/l AM281 or rimonabant. We simultaneously measured the
late apoptotic marker represented as fragmented nuclei using Hoechst 33342 staining
(Molecular Probes, Invitrogen). Few fragmented nuclei were observed in DOX-treated cells
whereas no such nuclei were present in normal, AM281, or rimonabant pretreated samples.
Thus, pretreatment with either AM281 or rimonabant protects H9c2 cells from DOX-induced
apoptosis as shown by early-to-late apoptotic markers.
Pretreatment for 2 h (followed by continuous treatment during the 18 h DOX exposure) with
CB2 agonist JWH133, CB1 agonist HU210, CB2 antagonists (AM630 and SR144528) (1 μmol/
l each) did not have any protective effect against DOX-induced cell death and apoptosis (Fig.
4). Interestingly, CB1 agonist HU210 by itself significantly enhanced apoptosis (Fig. 4).
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CB1 antagonists prevent DOX-induced apoptosis of cardiomyocytes in vivo
Myocardial caspase-3-dependent apoptosis was previously described in the mouse model of
DOX-induced heart failure (14,24). We have observed significant level of cleaved caspase-3
in samples of heart tissue from DOX-treated mice. Two representative samples from each group
are shown in Figure 5A. The total absence of cleaved caspase-3 in AM281 or rimonabant
pretreated mice indicates the protective effect of CB1 antagonists against apoptosis.
As shown in Figure 5B, DOX treatment induced marked elevation in the caspase-3 activity in
the myocardial tissues (~2.8-fold) compared with control mice. Rimonabant/AM281
pretreatment of mice prevented the DOX-induced increase in caspase-3 activity.
We also analyzed gene expression of 2 apoptotic markers, caspase-3 and caspase-9, from the
same group of heart samples. In agreement with the increased protein expression, caspase-3
mRNA was also increased significantly by DOX treatment to 4.5 ± 0.7-fold over control group,
and this increase was markedly attenuated by AM281 or rimonabant pretreatment (1.6 ± 0.2
and 0.9 ± 0.2, respectively) (Fig. 5C). Doxorubicin also induced a 10.4 ± 1.6-fold increase in
caspase-9 gene expression compared with normal hearts, which was reduced by pretreatment
with AM281 or rimonabant to a 1.8 ± 0.6 and 2.1 ± 0.6-fold change, respectively. In vehicle-
treated control mice, AM281 or rimonabant treatment did not affect caspase-3 and caspase-9
gene expression.
CB1 receptor antagonists attenuate DOX-induced DNA fragmentation
Doxorubicin also increased myocardial TUNEL staining in the myocardium, which was largely
attenuated by either rimonabant or AM281 pretreatment (Fig. 6A).
To strengthen the preceding conclusion, we used 2 additional quantitative methods.
Doxorubicin-induced DNA fragmentations in the myocardial tissue was increased 2.9- and
4.5-fold compared with sham control measured by quantitative TUNEL and DNA
fragmentation assays, and was largely attenuated by pretreatment with CB1 antagonists (Figs.
6B and 6C).
Effects of DOX on myocardial CB1 and CB2 receptors
Myocardial CB1 receptor protein levels were unchanged in DOX-treated mice as documented
by using Western blots (Fig. 7A). The specificity of the antibodies used was confirmed by the
absence of a specific band using myocardial tissue from a CB1 knockout mouse. Myocardial
CB1 or CB2 receptor gene expression was not affected by DOX treatment in mice as verified
using reverse transcription-polymerase chain reaction (Fig. 7B) as well as quantitative real-
time polymerase chain reaction where the CB1 or CB2 receptor gene expressions were
normalized to beta-actin gene expression (Fig. 7C). Similar results were obtained in
cardiomyocytes (Fig. 7D, lower part).
DOX increased endocannabinoid AEA content both in vivo and in vitro
Doxorubicin treatment resulted in increased AEA but not 2-AG content in the myocardium
(Fig. 7E). Similarly, elevated AEA levels were detected in DOX-treated H9c2 cells as
compared with the vehicle-treated control cells (Fig. 7F).
Discussion
The natural ligands of CB1 receptors are the endocannabinoids AEA and 2-AG, both of which
are present in the myocardium, along with CB1 receptors (16,17). Numerous previous
experimental studies have demonstrated that activation of the endocannabinoid system may
contribute to the hypotension and compromised cardiovascular function in a variety of
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pathophysiological states (e.g., hemorrhagic, endotoxic, and cardiogenic shock, advanced liver
cirrhosis, and cirrhotic cardiomyopathy) through the activation of myocardial and vascular
CB1 receptors. Importantly, in all these conditions, the cardiovascular depressive effects could
be prevented or reversed by various CB1 antagonists (16,17).
Our present findings provide evidence that endocannabinoid AEA is overproduced in a well-
established model of DOX-induced acute heart failure, and CB1 antagonists improve
compromised contractile function. Furthermore, we show that CB1 antagonists exert powerful
cytoprotective effect in cardiomyocytes against DOX-induced cardiotoxicity both in vivo and
in vitro by reducing apoptosis, offering a novel approach for the prevention of this devastating
complication of chemotherapy.
There is limited and conflicting information about the role of cannabinoid receptor activation
in cell-protective mechanisms against ischemia/reperfusion (I/R) damage in the heart (16,17,
25). A major limitation of these studies is the use of buffer-perfused isolated heart preparations,
in which the effects of endocannabinoids and synthetic agonists on immune cells, which are
pivotal in reperfusion damage, cannot be studied, as well as the use of nonselective cannabinoid
ligands. In a more relevant in vivo model of myocardial I/R injury induced by coronary
occlusion/reocclusion in anesthetized mice, the published evidence points to the protective role
of CB2 but not CB1 receptor activation (CB2 activation on immune cells was responsible for
the reduced leukocyte-dependent myocardial damage associated with reperfusion) (26). The
presence of CB2 receptors in the myocardium and their function has never been convincingly
demonstrated so far (selective CB2 receptor agonists do not decrease blood pressure and
myocardial contractility in vivo, in contrast to the well-known hypotensive and
cardiodepressive effects of CB1 agonists). Two studies using rat models of acute and chronic
myocardial infarction have demonstrated that endocannabinoids contribute to the hypotension
and cardiodepression associated with acute cardiogenic shock, which could be attenuated by
CB1 antagonists (27,28). Cannabinoid-1 receptor antagonist AM251 was suggested to promote
remodeling in the later chronic heart failure study, but it tended to improve survival. In contrast,
the treatment with CB1 agonist HU210 was shown to prevent endothelial dysfunction, but it
increased left ventricular end-diastolic pressure (28). However, the major limitation of the
previous study (28) is the use of high dose of HU210, which was previously reported to cause
severe psychotropic side effects and hypothermia, and the use of suboptimal doses of CB1
antagonist AM251 (17). Furthermore, HU210 was previously demonstrated to exert
antiarrhythmic, anti-inflammatory properties, and to decrease myocardial damage in perfused
hearts by mechanisms not related to CB1 activation, complicating the interpretation of these
results (17).
In our present study, we used a well-established mouse model of DOX-induced acute heart
failure in which the cardiac dysfunction has been characterized by using either
echocardiography (14,21), tissue Doppler imaging (22), or pressure–volume systems (6,15).
Importantly, in this model, a direct correlation between the degree of myocardial apoptosis and
the severity of DOX-induced heart failure has been established (22). Apoptotic cell death is a
key component in DOX-induced cardiotoxicity as established by numerous studies (11,13,
14,24,29), and also indicated by the present findings.
Here we demonstrate that pharmacologic inhibition of CB1 receptors with rimonabant and
AM281 conferred marked protection against DOX-induced cardiac dysfunction and cell death
both in vivo and in vitro. The protective effect against DOX-induced cell death was not
observed with CB1 and CB2 agonists and CB2 antagonists in vitro. Thus, CB1 antagonists may
protect against DOX-induced cardiotoxicity by exerting potent cytoprotective effects on the
one hand, and by antagonizing the cardiodepression elicited by endocannabinoid AEA on the
other.
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The observed protective effect of CB1 antagonists and the DOX-induced increase in myocardial
AEA content may, therefore, suggest that DOX-induced cardiotoxicity is associated with and
mediated, at least in part, by activation of the endocannabinoid system. Collectively, the present
findings suggest that CB1 antagonists may represent a new cardioprotective strategy against
DOX-induced cardiotoxicity and perhaps other cardiovascular pathologies associated with
increased cell death. Further studies are warranted to investigate the underlying signaling
mechanisms of these beneficial effects.
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For expanded Materials and Methods, please see the online version of this article.
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Figure 1. Effects of CB1 Antagonists on DOX-Induced Cardiac Dysfunction
Effect of doxorubicin (DOX) on left ventricular systolic pressure (LVSP), left ventricular end-
diastolic pressure (LVEDP), LV maximum first derivative of ventricular pressure with respect
to time (+dP/dt), LV −dP/dt, heart rate, stroke work, ejection fraction, and cardiac output and
tau (Weiss and Glantz) in mice. Mice were pretreated either with vehicle, rimonabant, or
AM281, and treated with either vehicle or DOX, as indicated in the Methods section.
Hemodynamic parameters were measured 5 days after DOX administration. Results are mean
± standard error of the mean of 7 to 13 experiments in each group. *p < 0.05 versus vehicle;
#p < 0.05 versus DOX. CB1 = cannabinoid-1.
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Figure 2. Effect of CB1 Antagonists on DOX-Induced Depression of Load-Independent Indexes of
Cardiac Contractility
(A) Representative pressure–volume (P–V) loops obtained with a P–V conductance catheter
system at different preloads after vena cava occlusion, showing differences in the end-systolic
P–V relation (ESPVR) and between mice pretreated with vehicle, rimonabant, or AM281 and
treated with vehicle or DOX. The less steep ESPVR in DOX-treated mice indicates decreased
contractile function, which was improved by CB1 antagonists. (B) Effects of CB1 antagonists
on DOX-induced depression of load-independent indexes of cardiac contractility. Results are
mean ± standard error of the mean of 9 to 18 experiments in each group. *p < 0.05 versus
vehicle; #p < 0.05 versus DOX. EDV = end-diastolic volume relation; ESPVR or Emax = end-
systolic pressure–volume relation; PRSW = preload-recruitable stroke work; other
abbreviations as in Figure 1.
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Figure 3. Effects of CB1 Antagonists on DOX-Induced Cell Death and Apoptosis In Vitro
(A) Effects of CB1 antagonists on cell viability measured by XTT assays. AM281 and
rimonabant (1 μmol/l) prevent cell death induced by 1 or 5 μmol/l of DOX. *p < 0.05 versus
control group; #p < 0.05 versus DOX (n = 4). (B) Effects of CB1 antagonists on the early
apoptosis marker fluorescent annexin V conjugate (Annexin V-FITC) and cell death detection
dye propidium iodide (PI) measured by flow cytometric analysis of H9c2. Representative data
from 3 experiments analyzed. (C) Effects of CB1 antagonists on active caspase expression
(green) and nuclear staining pattern by Hoechst 33342 dye (blue). Please also note that some
of the nuclei are fragmented in DOX-treated cells (indicative of late apoptosis), but not in
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CB1 antagonist-treated or control cells. Representative data from at least 15 experiments
analyzed. Abbreviations as in Figure 1.
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Figure 4. Effects of CB1 Agonist, CB2 Antagonists, and Agonists on DOX-Induced Apoptosis in
H9c2 In Vitro
Effects of CB1 agonist, CB2 antagonists, and agonists on the early apoptosis marker Annexin
V-FITC and cell death detection dye propidium iodide (PI) measured by flow cytometric
analysis of H9c2. Representative data from 3 experiments analyzed. Abbreviations as in
Figures 1 and 3.
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Figure 5. Effects of CB1 Antagonists on DOX-Induced Apoptosis In Vivo
(A) Effects of CB1 antagonists on DOX-induced caspase-3 activation analyzed by Western
blot from heart tissue homogenates. Treatment with rimonabant or AM281 reduced myocardial
caspase-3 activation in DOX-treated mice. The blot was also probed for beta-actin level for
loading control. Representative blot from at least 5 experiments. (B) Effects of CB1 antagonists
on DOX-induced caspase-3 activity analyzed by colorimetric method from heart tissue
homogenates. Treatment with rimonabant or AM281 reduced caspase-3 activity in DOX-
treated mice. *p < 0.05 versus vehicle; #p < 0.05 versus DOX (n = 4 per group). (C) Effects
of CB1 antagonists on DOX-induced caspase-3 and caspase-9 gene expression. Data were
analyzed with 2 housekeeping genes, and data presented here were normalized with beta-actin.
Treatment with rimonabant or AM281 reduced myocardial caspase-3 and caspase-9 gene
expression in DOX-treated mice. *p < 0.05 versus vehicle; #p < 0.05 versus DOX (n = 6 to 15
per group). Abbreviations as in Figure 1.
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Figure 6. Effects of Rimonabant and AM281 on DOX-Induced Myocardial Apoptosis In Vivo
Determined by TUNEL and DNA Fragmentation Assay
(A) Note the increased myocardial terminal deoxynucleotidyltransferase-mediated nick-end
labeling (TUNEL) staining from doxorubicin (DOX)-treated mice (brown). Treatment with
cannabinoid-1 antagonist rimonabant and AM281 reduced myocardial TUNEL staining in
DOX-treated mice. Similar immunohistochemical profiles were seen in n = 3 hearts per group.
Quantitative measurements were carried out in 20 fields per group. *p < 0.05 versus vehicle
(Veh); #p < 0.05 versus DOX. (B) Effects of rimonabant and AM281 on DOX-induced
myocardial apoptosis in vivo by TUNEL assay. *p < 0.05 versus vehicle; #p < 0.05 versus
DOX (n = 4 per group). (C) Effects of rimonabant and AM281 on DOX-induced
deoxyribonucleic acid (DNA) fragmentation in vivo. Changes are expressed in % of
myocardial DNA fragmentation in vehicle-treated mice (100%). *p < 0.05 versus vehicle; #p
< 0.05 versus DOX (n = 4 per group). Eu = Europium.
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Figure 7. Effects of DOX on Myocardial Endocannabinoid Content and CB 1/2 Receptor Expression
(A) Evidence of CB1 receptor protein expression in total lysate of DOX-treated mouse heart
tissue homogenate by Western blot analysis. (B and D) Evidence of CB1 and CB2 receptor
gene expression by semiquantitative reverse transcription-polymerase chain reaction (RT-
PCR) from complementary deoxyribonucleic acid of both untreated and DOX-treated mouse
heart samples (B) and cardiomyocytes (D). (C) Evidence of CB1 receptor and CB2 receptor
gene expression in heart tissue by quantitative real-time PCR after normalization to beta-actin
(n = 6 to 15). (E) Effect of DOX on anandamide (AEA) and 2-arachidonylglycerol (2-AG)
production in vivo by liquid chromatography mass spectrometry (LCMS) analysis of heart
tissue samples. *p < 0.05 versus vehicle (n = 6). (F) Effect of DOX (1 μM for 2 h) on AEA
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and 2-AG production in vitro by LCMS analysis of H9c2 cells. Increased AEA levels were
observed in doxorubicin treated samples. *p < 0.05 versus vehicle (n = 3). KO = knockout;
other abbreviations as in Figure 1.
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